Andrew H. Beck

Andrew H. Beck, MD, PhD is Co-Founder and Chief Science Officer of PathAI, the leading AI-powered pathology company, and formerly Associate Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical Center. Dr. Beck is widely regarded as one of the founders of modern computational pathology, having published seminal work on deep learning for pathology image analysis while at Harvard before founding PathAI in 2016 to translate academic advances in AI pathology into clinical-grade diagnostic and biomarker tools. Under his scientific leadership, PathAI has developed AI-powered pathology platforms deployed across major pharmaceutical companies for clinical trial biomarker assessment, drug development, and companion diagnostic development. His laboratory at Harvard generated landmark studies demonstrating that deep learning models applied to H&E-stained breast cancer slides can predict survival outcomes and identify immune infiltration patterns associated with treatment response, establishing AI-quantified tumor-infiltrating lymphocytes (TILs) as a reproducible, prognostic biomarker. Dr. Beck's PathAI platform has been used to develop AI-based biomarkers in clinical trials for liver fibrosis, NASH, breast cancer, and immunotherapy response, and several PathAI-derived assays are in regulatory pathways as companion diagnostics. He is a physician-scientist and practicing pathologist whose integration of clinical, academic, and industry perspectives has made him a defining figure in the transition of computational pathology from research to clinical reality.